Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB123667 in advanced solid tumors
jRCT2031220091Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of INCB123667 in Nonhematologic neoplasms, ovarian cancer, fallopian tube cancer (PFTC) and 8 more (21 arms), sponsored by Incyte. Primary endpoints: Occurrence of dose-limiting toxicities, Treatment-emergent adverse events and 3 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
INCB123667
03
Conditions
Nonhematologic neoplasmsovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2031220091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220091.